Ordr Partners with e-Quip to Deliver Improved Connected Medical Device Visibility and Security for UK Healthcare Market

Combined Solution Provides the Real-Time Insight and Detailed Information Needed to Properly Manage and Secure the Increasing Number of Connected Medical Devices

Ordr, the leader in connected device security, today announced it has partnered with the UK’s leading medical device asset management provider Integra e-Quip Ltd. The two companies have teamed up to deliver a best-in-class clinical asset management and security solution to healthcare organizations throughout the UK.

e-Quip’s Computerised Maintenance Management System (CMMS) maintains an inventory of all connected medical devices on a network, orchestrating critical processes such as device maintenance, procurement planning, and compliance assurance. Ordr’s AI-powered platform automatically discovers and classifies all devices connecting to a network, including IoMT (Internet of Medical Things) devices. The insights delivered by Ordr help teams identify and understand potential device risks like the presence of obsolete operating systems, manufacturer recalls, vulnerabilities, weak passwords, or outdated certificates.

Ordr is critical to address a number of UK compliance initiatives including:

NHS Trust Data Security Protection Toolkit (DSPT) compliance
Cyber Essentials
NIS2 Directive

The integration between e-Quip and Ordr enables clinical engineering departments and IT teams to have real-time, granular visibility into all connected medical devices, ensuring that the e-Quip CMMS always remains up-to-date with accurate details. Ordr helps with the challenging activity of asset reconciliation – identifying authorized medical devices in the e-Quip system that are not on the network, or discovering deployed devices that are not in the CMMS. This is critical for real-time inventory, and to prioritize vulnerabilities and schedule patch management in clinical settings. In addition, with Ordr’s strong capabilities in behavioral baselining and threat detection, the combined solution can identify devices that are behaving abnormally, automatically initiating the correct e-Quip workflows to address these risks.

“Integra e-Quip is dedicated to making it easy for healthcare organizations to manage the myriad of medical devices they have connected to their networks. Doing this efficiently and effectively requires advanced visibility,” said Dal Jdali, CEO, at Integra e-Quip. “By teaming with Ordr we can provide customers with that real-time analysis of connected devices, helping them gain an accurate understanding of their attack surface – and the ability to identify and address potential risks.”

Ordr’s platform enables clinical engineering and IT teams across NHS trusts to not only discover and classify every connected device in the hospital, but also identify medical devices that have critical vulnerabilities that need to be patched. Armed with this information, the e-Quip system can then schedule and prioritize patching efforts, ensuring teams are up to date with potential risks across their environment – and are mitigating any risks in a timely manner.

“The global healthcare industry faces a unique set of challenges when it comes to managing and securing its connected devices,” added Pandian Gnanprakasam, co-founder and Chief Product Officer, Ordr. “Every NHS Trust is responsible for protecting all the connected devices operating in their networks whether they are aware of them or not. Ordr discovers, identifies, and assesses all of an organization’s connected assets giving healthcare security teams a comprehensive view into the activities of each device on their network, and a full understanding of the risks each pose. With operating systems being brought to end-of-life and devices not manufactured with security in mind, it is critical for teams to have the tools to access risk and quickly apply security policy protections.”

e-Quip CMMS is used across the U.K. by many National Health Services (NHS) trusts and their clinical engineering teams. The combined solution addresses the challenges NHS Trusts face in managing and securing the growing number of connected medical devices that today’s healthcare organizations have come to depend upon.

For more information about how Ordr and e-Quip can help your organization discover and secure every connected medical device, please click here.

SourceOrdr

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version